RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human clinical evidence

Tesamorelin research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

Randomised controlled studies have investigated tesamorelin, a growth hormone-releasing hormone analogue, using visceral-adipose, liver-fat, IGF-I and metabolic endpoints in defined adult populations.

Areas studied

  • Growth hormone-releasing hormone signalling
  • IGF-I response
  • Body-composition imaging
  • Metabolic endpoints

Limitations and investigational status

The cited evidence comes from selected clinical populations, particularly people living with HIV and abdominal fat accumulation. It should not be generalised beyond those study settings or to uncontrolled research material.

References

  1. 1Falutz et al. - Journal of Clinical Endocrinology and Metabolism, 2010
  2. 2Stanley et al. - JAMA, 2014

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.